AtheroGenics Soars 64 Percent On AGI-1067 Phase IIb Results Sep. 29, 2004 By Aaron Lorenzo No Comments AtheroGenics Inc. saw its share value skyrocket on positive clinical trial results that revealed its lead drug candidate cut plaque buildup in heart disease patients. (BioWorld Today)Read More
Emisphere To Deliver rhGH For Novartis In Potential $34M Deal Sep. 24, 2004 By Aaron Lorenzo No Comments
Emisphere To Deliver rhGH For Novartis In Potential $34M Deal Sep. 24, 2004 By Aaron Lorenzo No Comments
